Here are three things to know.
1. Glatopa, manufactured by Novartis’ subsidiary Sandoz, is intended for patients with relapsing forms of multiple sclerosis. The drug is administered as an injection three times a week.
2. Sandoz earned FDA approval for a smaller dosage of Glatopa in 2015. Contamination issues at a production plant delayed regulatory approval of the new dosage form until this month.
3. Glatopa represents the second generic version of Teva’s brand-name drug to enter the market. Mylan launched its version in 2017.
More articles on supply chain:
FDA OKs Novartis’ generic version of Teva’s MS drug: 3 things to know
Walgreens is reportedly in talks to purchase AmerisourceBergen: 7 things to know
Philips recalls HeartStart MRx Defibrillator: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.